Adverse effects of feminizing hormone therapy in transgender women

Abstract

Feminizing hormone therapy deals with the administration of estrogen and antiandrogenic with the aim of reducing gender dysphoria in transgender women. However, this therapy is linkin with appearance of adverse effects. The objective if this study was to identify the main adverse effects of feminizing hormone therapy, through a bibliographic review, for their integration into transgender women’s medical care. A literature review was carried out in four databases; PubMed, EBSCO, BVS and ScienceDirect; with a total of 229 articles which were narrow down by the Prisma 2020 model, resulting in a total of 11 studies. The results showed an increased risk of venous Thromboembolism of up to 45 times, HOMA rates of 47 - 72% compared to cisgender men. In conclusion, feminizing hormonal therapy comes with cardiovascular and metabolic risks and a possible carcinogenic effect. Your safety depends on careful medical supervision. Further studies are needed on its long-term effects on transgender individuals.